J. Goldman & Co’s Biogen BIIB Stock Holding History

J. Goldman & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,600	Closed	-$644K	–	576
2025 Q3	$644K	Buy	+4,600	New	+$622K	0.02%	367
2024 Q3	–	Sell	-40,000	Closed	-$9.27M	–	468
2024 Q2	$9.27M	Buy	40,000 +20,000	+100%	+$4.35M	0.26%	119
2024 Q1	$4.31M	Buy	+20,000	New	+$4.68M	0.14%	155
2023 Q2	–	Sell	-17,500	Closed	-$4.87M	–	384
2023 Q1	$4.87M	Sell	17,500 -77,500	-82%	-$21.4M	0.2%	145
2022 Q4	$26.3M	Buy	95,000 +78,700	+483%	+$22.2M	1.29%	15
2022 Q3	$4.35M	Buy	+16,300	New	+$3.46M	0.21%	132
2021 Q1	–	Sell	-36,000	Closed	-$8.81M	–	437
2020 Q4	$8.81M	Buy	+36,000	New	+$9.29M	0.45%	62

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's BIIB Position: Q4 2023 in Review

J. Goldman & Co sold out of Biogen (BIIB) in Q4 2023, closing a stake of 56,921 shares — an estimated $14M sold.

J. Goldman & Co first reported a position in BIIB in Q4 2020 and held it in 6 quarters. The position peaked at $14.6M in Q3 2023. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

J. Goldman & Co reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 56,921 Biogen shares in Q4 2023, an estimated $14M.
J. Goldman & Co first reported a position in Biogen in Q4 2020 and held it in 6 quarters.
J. Goldman & Co's Biogen position peaked at $14.6M in Q3 2023.
1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.